A subset of high-risk neuroblastoma patients who have a poor end of Induction response may benefit from receiving chemoimmunotherapy, as bridge therapy, prior to Consolidation. Prospective studies evaluating this therapeutic approach and improved identification of biomarkers of response are warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728546 | PMC |
| http://dx.doi.org/10.1002/cncr.34267 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improving neuroblastoma risk prediction through a polygenic risk score derived from genome-wide association study-identified loci.
Chin J Cancer Res
January 2025
Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
Objective: Neuroblastoma is the most common extracranial solid tumor in children and has complex genetic underpinnings. Previous genome-wide association studies (GWASs) have identified many loci associated with neuroblastoma susceptibility; however, their application in risk prediction for Chinese children has not been systematically explored. This study seeks to enhance neuroblastoma risk prediction by validating these loci and evaluating their performance in polygenic risk models.
View Article and Find Full Text PDFA phase II trial of Naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission.
Clin Cancer Res
March 2025
Memorial Sloan Kettering Cancer Center, New York City, NY, United States.
Purpose: Naxitamab is a humanized form of the murine anti-GD2 monoclonal antibody (mAb) 3F8. In an international trial, naxitamab+GM-CSF was effective against chemo-resistant high-risk neuroblastoma (HR-NB), leading to approval by the Food and Drug Administration. We now report results with patients in 1st complete remission (CR).
View Article and Find Full Text PDF15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.
Curr Oncol Rep
March 2025
Pediatric Oncology Department, Children's Cancer Hospital Egypt, 57357, 1-Sekket Elemam-Sayeda Zeinab, Cairo, Egypt.
Purpose Of Review: This review provides a comprehensive understanding of the ALK gene, encompassing its prevalence, genetic alterations, and significance in neuroblastoma diagnosis, outcome prediction, and targeted therapy utilization. The insights presented aim to inform future research directions and clinical practices in this field.
Recent Findings: High risk neuroblastoma, comprising approximately 50% of all cases, presents a particularly poor prognosis.
Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.
Front Oncol
February 2025
Research & Frontiers in AI Department, Quantitative Imaging Biomarkers in Medicine, Quibim SL, Valencia, Spain.
Introduction: Neuroblastoma, the most prevalent solid cancer in children, presents significant biological and clinical heterogeneity. This inherent heterogeneity underscores the need for more precise prognostic markers at the time of diagnosis to enhance patient stratification, allowing for more personalized treatment strategies. In response, this investigation developed a machine learning model using clinical, molecular, and magnetic resonance (MR) radiomics features at diagnosis to predict patient's overall survival (OS) and improve their risk stratification.
View Article and Find Full Text PDFEffect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China.
World J Stem Cells
February 2025
Department of Pediatric Hematology Oncology, Guangdong Women and Children Hospital, Guangzhou 510000, Guangdong Province, China.
Background: Despite advances in treatment, the prognosis for patients with high-risk pediatric solid tumors remains dismal. Tandem autologous stem cell transplantation (ASCT) offers promise for improving outcomes in these patients. This study aimed to examine the efficacy and prognostic factors of tandem ASCT in pediatric patients with high-risk solid tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!